Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC). is a research paper published in Journal of Clinical Oncology (2010). On theSindex it has a DataRank of 3.0. It has been cited 53 times, with 53 citing works in its 1-hop citation network.
7531 Background: IPI is a fully human monoclonal antibody that potentiates immune response by selectively inhibiting CTLA-4. CA184- 041 is a randomized, double-blind phase II study of first-line IPI in recurrent/metastatic lung cancer in combination with P (175 mg/m2)/C (AUC=6). Methods: 203 pts with chemotherapy-naive, recurrent or stage IIIb/IV NSCLC were randomized 1:1:1 to receive either: IPI (10 mg/kg IV q3wks) + concurrent (CON) IV P/C (175 mg/m2 and AUC=6, q3wks); or IPI + sequential (SEQ) P/C, or P/C alone (PBO). After P/C, IPI was administered as continuation maintenance therapy q12 wks until toxicity or disease progression. Efficacy was assessed by mWHO and novel immune- related response criteria (irRC), providing a more comprehensive evaluation of immunotherapeutics (Clin Canc Res 2009;15:7412). The primary objective compared immune-related progression-free survival (irPFS) between CON and PBO and SEQ and PBO using a log-rank test with one-sided alpha of 0.1. Results: Baseline characteristics were generally balanced between the arms. The Table presents PFS and immature OS using the irRC and mWHO. IPI plus P/C was generally well tolerated. Grade (Gr) 3/4 AEs were 58%, 52% and 42% for CON, SEQ and PBO, respectively. Generally reversible and manageableGr 3/4 immune-related AEs (pre-selected to reflect IPI mechanism of action) were 20% and 15% for CON and SEQ, respectively. Conclusions: Ipilimumab addition to P/C, in concurrent and sequential regimens, extended irPFS in NSCLC pts compared with P/C alone. Safety results suggest a moderate added toxicity to the P/C regimen due to ipilimumab with no novel toxicities and rare and comparable drug-related death rates across all arms. These results support further investigation of ipilimumab in NSCLC. IPI + P/C P/C CON (n = 70) SEQ (n = 68) PBO (n = 66) irPFS Median mo 5.52 5.68 4.63 95% CI 4.17, 6.74 4.76, 7.79 4.14, 5.52 p value 0.094 0.026 HR 0.775 0.686 95% CI 0.53, 1.13 0.47, 1.01 PFS Median mo 4.11 5.13 4.21 95% CI 2.76, 5.32 4.17, 5.72 2.76, 5.32 p value 0.250 0.024 HR 0.882 0.691 95% CI 0.61,1.27 0.48, 1.00 OS Median mo 11.01 11.56 9.99 95% CI 8.38, 12.75 9.26, 14.39 6.97, 13.63 p value 0.429 0.104 HR 0.962 0.748 95% CI 0.63, 1.48 0.48, 1.18 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb, Infinity Pharmaceuticals AstraZeneca, Boehringer Ingelheim, Genentech, Lilly, Merck, Roche Bristol-Myers Squibb, Infinity Pharmaceuticals AstraZeneca, Lilly, Merck, Roche Bristol-Myers Squibb
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Base Score Contribution
0.598
From this paper's citation signal
Citation Network Contribution
2.4
From 48 citing papers with measurable signal
Ranked by citation count — the same ordering the engine uses when summing log1p(Cq) over citers.
DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 20% comes from its base citations and 80% from the citation network (48 citing papers contributed measurable signal).
Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.
Click a node to highlight its connections. Use scroll to zoom. Drag to pan.